Compare · DXCM vs PLSE
DXCM vs PLSE
Side-by-side comparison of DexCom Inc. (DXCM) and Pulse Biosciences Inc (PLSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PLSE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.46B, about 16.4x PLSE ($1.79B).
- Over the past year, DXCM is down 10.6% and PLSE is up 60.5% - PLSE leads by 71.1 points.
- DXCM has hit the wire 5 times in the past 4 weeks while PLSE has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 6 for PLSE).
- Company
- DexCom Inc.
- Pulse Biosciences Inc
- Price
- $76.34+1.82%
- $25.89-1.37%
- Market cap
- $29.46B
- $1.79B
- 1M return
- +2.09%
- +3.66%
- 1Y return
- -10.56%
- +60.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Latest DXCM
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
Latest PLSE
- SEC Form 4 filed by Director Zanganeh Mahkam
- SEC Form 4 filed by Director Van Den Broek Richard
- SEC Form 4 filed by Director Duggan Robert W
- SEC Form 4 filed by Director Soni Manmeet Singh
- SEC Form 4 filed by Director Sainz Maria
- Pulse Biosciences Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
- Canaccord Genuity initiated coverage on Pulse Biosciences with a new price target
- Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026